Resistance of BRAFV600E-mutant melanoma to Vemurafenib: a senescence-induced swing from differentiation to blastulation followed by proliferation Felikss Rumnieks, Ninel M. Vainshelbaum, Kristine Salmina, Maria Lazovska, Madara Kreismane, Dace Pjanova, Justs Zalums, Kristine Vaivode, Daniel Ross Saliba, Pawel Zayakin, Talivaldis Freivalds, Dmitry Perminov, Andrzej Kasperski, Harry Scherthan, Mark Steven Cragg, Jekaterina Erenpreisa Cancer Letters, 2026 Resistance to Vemurafenib (VEM), a targeted BRAFV600E inhibitor, was examined in the metastatic paratetraploid (XX, abnormal Y chromosome) melanoma cell line, SkMel28. During the first week of treatment, pERK suppression coincided with transcriptomic and phenotypic changes related to senescence, autophagy/mitophagy, neuro-melanogenesis, and cell co-alignment. By the second week, MAPK–ERK signalling was restored, coinciding with surmounting the G1/S checkpoint, G2M checkpoint delay, mitotic slippage (MS), and downregulation of senescence and melanogenesis. The dynamics of melanogenesis and MS were highly correlated. By days 12–15, ∼8% of cells with melanin remnants exhibited hyperploidy and multinucleation, some arranged as rosettes, encased by a Zona pellucida-positive structure reminiscent of oocytes, zygotes, or blastulae, occasionally yielding cellularised sub-cells or stalling in diapause. These parasexual processes eventually ceased; cells resumed proliferative clonogenic growth and their initial mito-meiotic, mesenchymal profile. Transcriptomic analysis confirmed the reversal of their cell fate direction: from senescence-induced neuro-melanogenesis to its suppression and activation of female meiosis–like and mitosis states. The transition point of this cell-fate reversal coincided with S-phase resumption, highlighted by replication delay and activation of the FOS–TEAD/Hippo axis of the “female pregnancy” (stress-response, embryonal placentation, vascularisation, stemness, anti-apoptosis) gene ontology module. We conclude that resistance to VEM in SkMel28 cells encompasses the transition between three possible cell fates: (1) senescence/differentiation, (2) reprogramming/blastulation, and (3) recovery of the proliferative mito-meiotic profile. The coexpression of senescence, reprogramming and gametogenetic genes in a dataset of late-stage melanoma patient samples supports these results. • Vemurafenib targeting BRAFV600E metastatic melanoma acts in a multi-step process • ERK suppression induces senescence and neuro-melanogenesis; reinitiated pERK activates ‘female pregnancy’ • Ontogeny reversal creates migratory or dormant multinucleated rosette-like “embryos” • Cellularised offspring resume proliferation and return to mito-meiotic profile • Senescence, stemness, and gametogenesis are coexpressed in primary melanoma
SARS-CoV-2 Infection and Vaccination, Immune Dysregulation, and Cancer Dace Pjanova, Aysha Rafeeque Vaccines, 2026 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection induces heterogeneous immune responses that influence both acute disease severity and long-term immune remodeling. A key question in the context of infection and vaccination is whether SARS-CoV-2 exerts direct oncogenic effects or instead acts as a transient immunological stressor capable of reinforcing tumor-permissive pathways. Current evidence does not support classical viral oncogenesis. Rather, severe infection is characterized by early interferon (IFN) imbalance followed by NF-κB-dominant inflammatory amplification, promoting sustained IL-6/JAK–STAT3 and MAPK signaling, chronic cytokine production, metabolic reprogramming, and impaired antitumor immune surveillance. At the molecular level, viral structural proteins modulate host signaling networks. The spike (S1) protein engages TLR2/TLR4–MyD88 pathways, activating NF-κB and MAPK cascades, while the membrane (M) protein reinforces NF-κB–STAT3 circuits linked to epithelial–mesenchymal transition and inflammatory gene expression. These mechanisms intensify pre-existing oncogenic signaling without initiating malignant transformation. Tissue-specific responses are further shaped by IFN competence, renin–angiotensin system balance, and metabolic context. In parallel, immune evasion programs shared by chronic viral infection and cancer, including checkpoint upregulation, impaired antigen presentation, and suppressive myeloid expansion, may be transiently reinforced following severe infection. In contrast, SARS-CoV-2 vaccination induces spatially restricted, self-limited innate activation without sustained inflammatory signaling or persistent antigen exposure. By preventing severe disease and chronic immune dysregulation, vaccination interrupts pathways hypothesized to intersect with cancer biology, with no evidence of increased cancer incidence. Ongoing longitudinal studies are required to clarify the long-term oncologic implications of post-infectious immune remodeling.
IgA class-switched CD27-CD21+B cells in IgA nephropathy Anna Popova, Baiba Slisere, Karlis Racenis, Viktorija Kuzema, Roberts Karklins, Mikus Saulite, Janis Seilis, Anna Jana Saulite, Aiga Vasilvolfa, Kristine Vaivode, Dace Pjanova, Juta Kroica, Harijs Cernevskis, Aivars Lejnieks, Aivars Petersons, Kristine Oleinika Nephrology Dialysis Transplantation, 2025 Background Immunoglobulin A nephropathy (IgAN) is characterized by the production of galactose-deficient IgA1 (GdIgA1) antibodies. As the source of pathogenic antibodies, B cells are central to IgAN pathogenesis, but the B cell activation pathways as well as the potential B cell source of dysregulated IgA secretion remain unknown. Methods We carried out flow cytometry analysis of peripheral blood B cells in patients with IgAN and control subjects with a focus on IgA-expressing B cells to uncover the pathways of B cell activation in IgAN and how these could give rise to pathogenic GdIgA1 antibodies. Results In addition to global changes in the B cell landscape—expansion of naïve and reduction in memory B cells—IgAN patients present with an increased frequency of IgA-expressing B cells that lack the classical memory marker CD27, but are CD21+. IgAN patients furthermore have an expanded population of IgA+ antibody-secreting cells, which correlate with serum IgA levels. Both IgA+ plasmabalsts and CD27− B cells co-express GdIgA1. Implicating dysregulation at mucosal surfaces as the driver of such B cell differentiation, we found a correlation between lipopolysaccharide in the serum and IgA+CD27− B cell frequency. Conclusion We propose that dysregulated immunity in the mucosa may drive de novo B cell activation within germinal centres, giving rise to IgA+CD27− B cells and subsequently IgA-producing plasmablasts. These data integrate B cells into the paradigm of IgAN pathogenesis and allow further investigation of this pathway to uncover biomarkers and develop therapeutic interventions.
Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028 M. Donia, H. Jespersen, M. Jalving, R. Lee, H. Eriksson, C. Hoeller, M. Hernberg, I. Gavrilova, L. Kandolf, G. Liszkay, H. Helgadottir, A. Zhukavets, D. Pjanova, I. Marquez-Rodas, B. Neyns, H. Westgeest, I. Pourmir, P. Sobczuk, E. Ellebaek, T. Amaral ESMO Open, 2025 BACKGROUND: Therapeutic advances have reshaped the treatment landscape for patients with resectable melanoma, particularly for those with stage IIB/C and stage III disease. In this article, we discuss the current status and future outlook of adjuvant immunotherapy for melanoma in Europe. RESULTS: Adjuvant immunotherapy offers significant benefits in terms of recurrence-free survival and distant metastasis-free survival. Uncertainties regarding overall survival (OS) benefits, however, remain. Trials such as Keynote-054, which are expected to provide crucial OS information, have delayed their final analyses until 2027. Additionally, real-world studies have raised questions about the correlation between recurrence-free survival/distant metastasis-free survival improvements observed in clinical trials and OS outcomes in routine clinical practice. These uncertainties have led to ongoing debates about the cost-effectiveness of adjuvant therapies, with disparities in reimbursement policies across Europe reflecting these concerns. CONCLUSION: Looking ahead to 2028, adjuvant immunotherapy will remain a key option of comprehensive melanoma care, particularly for patients with stage IIB/C and stage III with micrometastatic disease, where neoadjuvant immunotherapy is not feasible.
Bacteriophage–derived double-stranded rna (larifan) exerts variable effects on human blood monocytes depending on age and sex of donors , R. Dovhyi, M. Rudyk, , T. Serhiichuk, , Yu. Yumyna, , A. Dvukhriadkina, , K. Ostrovska, , D. Pjanova2,, , L. Skivka, and Ukrainian Biochemical Journal, 2024 To date, great attention is paid to sex and age differences in the therapeutic effectiveness of drugs, including those that impact the immune system. Bacteriophage-derived dsRNA is the main component of the medicinal product Larifan, which exhibits interferonogenic activity. This study aimed to estimate the effect of Larifan on the activation status of human peripheral blood monocytes collected from donors of different ages and sex. Blood samples were obtained from the healthy volunteers, divided into 4 groups: young men and young women aged from 20 to 39 years, aged men and aged women from 54 to 69 years old. EDTA-anticoagulated blood samples were exposed to 200 μg/ml Larifan for 30 min, cells were washed and treated to study phagocytic index, ROS generation and expression of phenotypic markers. Only live monocytes selected by flow cytometry were included in the analysis. It was shown that monocytes from young as well as from aged females turned out to be quite inert to the treatment with Larifan. Monocytes from young males after the treatment demonstrated a minor decrease in phagocytic activity and significant down-regulation of ROS generation. Monocytes from aged adults showed clear sex-based differences in the basal cell phenotype. Thus, compared to monocytes from women, the monocytes from men over 50 after the treatment with Larifan showed decreased phagocytic activity and CD86 expression along with increased CD206 expression. Taken together, these results indicate the need for further studies of Larifan focused on developing personalized treatment depending on the age and sex of an individual. Keywords: double-stranded RNA, Larifan, monocytes, phagocytosis, reactive oxygen species, sex and age differences
The Price of Human Evolution: Cancer-Testis Antigens, the Decline in Male Fertility and the Increase in Cancer Jekaterina Erenpreisa, Ninel Miriam Vainshelbaum, Marija Lazovska, Roberts Karklins, Kristine Salmina, Pawel Zayakin, Felikss Rumnieks, Inna Inashkina, Dace Pjanova, Juris Erenpreiss International Journal of Molecular Sciences, 2023 The increasing frequency of general and particularly male cancer coupled with the reduction in male fertility seen worldwide motivated us to seek a potential evolutionary link between these two phenomena, concerning the reproductive transcriptional modules observed in cancer and the expression of cancer-testis antigens (CTA). The phylostratigraphy analysis of the human genome allowed us to link the early evolutionary origin of cancer via the reproductive life cycles of the unicellulars and early multicellulars, potentially driving soma-germ transition, female meiosis, and the parthenogenesis of polyploid giant cancer cells (PGCCs), with the expansion of the CTA multi-families, very late during their evolution. CTA adaptation was aided by retrovirus domestication in the unstable genomes of mammals, for protecting male fertility in stress conditions, particularly that of humans, as compensation for the energy consumption of a large complex brain which also exploited retrotransposition. We found that the early and late evolutionary branches of human cancer are united by the immunity-proto-placental network, which evolved in the Cambrian and shares stress regulators with the finely-tuned sex determination system. We further propose that social stress and endocrine disruption caused by environmental pollution with organic materials, which alter sex determination in male foetuses and further spermatogenesis in adults, bias the development of PGCC-parthenogenetic cancer by default.
Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families John Charles A. Lacson, , Shawn A. Zamani, Luis Alberto Ribeiro Froes, Nandita Mitra, Lu Qian, Scarlet H. Doyle, Esther Azizi, Claudia Balestrini, D. Timothy Bishop, William Bruno, Blanca Carlos-Ortega, Francisco Cuellar, Anne E. Cust, David E. Elder, Anne-Marie Gerdes, Paola Ghiorzo, Thais C. Grazziotin, Nelleke A. Gruis, Johan Hansson, Marko Hočevar, Veronica Höiom, Elizabeth A. Holland, Christian Ingvar, Gilles Landman, Alejandra Larre-Borges, Graham J. Mann, Montserrat Molgo, Luciana Facure Moredo, Håkan Olsson, Jacoba J. Out-Luiting, Barbara Perić, Dace Pjanova, Susana Puig, Julio Salas-Alanis, Helen Schmid, Karin A. W. Wadt, Julia A. Newton-Bishop, Peter A. Kanetsky BMC Public Health, 2021
Association of HERV-K and LINE-1 hypomethylation with reduced disease-free survival in melanoma patients Maurizio Cardelli, Remco van Doorn, Lares Larcher, Michela Di Donato, Francesco Piacenza, Elisa Pierpaoli, Robertina Giacconi, Marco Malavolta, Sivaramakrishna Rachakonda, Nelleke A Gruis, Anders Molven, Per Arne Andresen, Dace Pjanova, Joost J van den Oord, Mauro Provinciali, Eduardo Nagore, Rajiv Kumar Epigenomics, 2020
Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT Nicholas J. Taylor, Nandita Mitra, Lu Qian, Marie-Françoise Avril, D. Timothy Bishop, Brigitte Bressac-de Paillerets, William Bruno, Donato Calista, Francisco Cuellar, Anne E. Cust, Florence Demenais, David E. Elder, Anne-Marie Gerdes, Paola Ghiorzo, Alisa M. Goldstein, Thais C. Grazziotin, Nelleke A. Gruis, Johan Hansson, Mark Harland, Nicholas K. Hayward, Marko Hocevar, Veronica Höiom, Elizabeth A. Holland, Christian Ingvar, Maria Teresa Landi, Gilles Landman, Alejandra Larre-Borges, Graham J. Mann, Eduardo Nagore, Håkan Olsson, Jane M. Palmer, Barbara Perić, Dace Pjanova, Antonia L. Pritchard, Susana Puig, Helen Schmid, Nienke van der Stoep, Margaret A. Tucker, Karin A.W. Wadt, Xiaohong R. Yang, Julia A. Newton-Bishop, Peter A. Kanetsky Journal of the American Academy of Dermatology, 2019
Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells Tiphaine Delaunay, Mathilde Violland, Nicolas Boisgerault, Soizic Dutoit, Virginie Vignard, Christian Münz, Monique Gannage, Brigitte Dréno, Kristine Vaivode, Dace Pjanova, Nathalie Labarrière, Yaohe Wang, E. Antonio Chiocca, Fabrice Le Boeuf, John C. Bell, Philippe Erbs, Frédéric Tangy, Marc Grégoire, Jean-François Fonteneau Oncoimmunology, 2018
Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families Nicholas J. Taylor, Nandita Mitra, Alisa M. Goldstein, Margaret A. Tucker, Marie-Françoise Avril, Esther Azizi, Wilma Bergman, D. Timothy Bishop, Brigitte Bressac-de Paillerets, William Bruno, Donato Calista, Lisa A. Cannon-Albright, Francisco Cuellar, Anne E. Cust, Florence Demenais, David E. Elder, Anne-Marie Gerdes, Paola Ghiorzo, Thais C. Grazziotin, Johan Hansson, Mark Harland, Nicholas K. Hayward, Marko Hocevar, Veronica Höiom, Christian Ingvar, Maria Teresa Landi, Gilles Landman, Alejandra Larre-Borges, Sancy A. Leachman, Graham J. Mann, Eduardo Nagore, Håkan Olsson, Jane M. Palmer, Barbara Perić, Dace Pjanova, Antonia Pritchard, Susana Puig, Nienke van der Stoep, Karin A.W. Wadt, Linda Whitaker, Xiaohong R. Yang, Julia A. Newton Bishop, Nelleke A. Gruis, Peter A. Kanetsky Journal of Investigative Dermatology, 2017
Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families Nicholas J. Taylor, Elizabeth A. Handorf, Nandita Mitra, Marie-Françoise Avril, Esther Azizi, Wilma Bergman, Giovanna Bianchi-Scarrà, D. Timothy Bishop, Brigitte Bressac-de Paillerets, Donato Calista, Lisa A. Cannon-Albright, Francisco Cuellar, Anne E. Cust, Florence Demenais, David E. Elder, Eitan Friedman, Anne-Marie Gerdes, Paola Ghiorzo, Alisa M. Goldstein, Thais C. Grazziotin, Johan Hansson, Nicholas K. Hayward, Marko Hocevar, Veronica Höiom, Elizabeth A. Holland, Christian Ingvar, Maria Teresa Landi, Gilles Landman, Alejandra Larre-Borges, Sancy A. Leachman, Graham J. Mann, Eduardo Nagore, Håkan Olsson, Jane Palmer, Barbara Perić, Dace Pjanova, Susana Puig, Helen Schmid, Nienke van der Stoep, Margaret A. Tucker, Karin A.W. Wadt, Linda Whitaker, Xiaohong R. Yang, Julia A. Newton Bishop, Nelleke A. Gruis, Peter A. Kanetsky Journal of Investigative Dermatology, 2016
Inherited variation in the PARP1 gene and survival from melanoma John R. Davies, Rosalyn Jewell, Paul Affleck, Gabriella M. Anic, Juliette Randerson‐Moor, Aija Ozola, Kathleen M. Egan, Faye Elliott, Zaida García‐Casado, Johan Hansson, Mark Harland, Veronica Höiom, Guan Jian, Göran Jönsson, Rajiv Kumar, Eduardo Nagore, Judith Wendt, Håkan Olsson, Jong Y. Park, Poulam Patel, Dace Pjanova, Susana Puig, Dirk Schadendorf, P. Sivaramakrishna Rachakonda, Helen Snowden, Alexander J. Stratigos, Dimitrios Bafaloukos, Zighereda Ogbah, Antje Sucker, Joost J. den Oord, Remco Doorn, Christy Walker, Ichiro Okamoto, Pascal Wolter, Jennifer H. Barrett, D. Timothy Bishop, Julia Newton‐Bishop International Journal of Cancer, 2014
An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: A BioGenoMEL study John R. Davies, Sinead Field, Juliette Randerson‐Moor, Mark Harland, Rajiv Kumar, Gabriella M. Anic, Eduardo Nagore, Johan Hansson, Veronica Höiom, Göran Jönsson, Nelleke A. Gruis, Jong Y. Park, Jian Guan, P. Sivaramakrishna Rachakonda, Judith Wendt, Dace Pjanova, Susana Puig, Dirk Schadendorf, Ichiro Okamoto, Håkan Olsson, Paul Affleck, Zaida García‐Casado, Joan Anton Puig‐Butille, Alexander J. Stratigos, Elizabeth Kodela, Simona Donina, Antje Sucker, Ismail Hosen, Kathleen M. Egan, Jennifer H. Barrett, Remco Doorn, D. Timothy Bishop, Julia Newton‐Bishop Pigment Cell and Melanoma Research, 2014
Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: A GenoMEL study Abdlsattar Zebary, Katarina Omholt, Remco van Doorn, Paola Ghiorzo, Katja Harbst, Carolina Hertzman Johansson, Veronica Höiom, Göran Jönsson, Dace Pjanova, Susana Puig, Giovanna B. Scarra, Mark Harland, Håkan Olsson, Suzanne Egyhazi Brage, Jane Palmer, Lena Kanter-Lewensohn, Ismini Vassilaki, Nicholas K. Hayward, Julia Newton-Bishop, Nelleke A. Gruis, Johan Hansson Journal of Investigative Dermatology, 2014
Melanoma prone families with CDK4 germline mutation: Phenotypic profile and associations with MC1R variants Hanne Eknes Puntervoll, Xiaohong R Yang, Hildegunn Høberg Vetti, Ingeborg M Bachmann, Marie Françoise Avril, Meriem Benfodda, Caterina Catricalà, Stéphane Dalle, Anne B Duval-Modeste, Paola Ghiorzo, Paola Grammatico, Mark Harland, Nicholas K Hayward, Hui-Han Hu, Thomas Jouary, Tanguy Martin-Denavit, Aija Ozola, Jane M Palmer, Lorenza Pastorino, Dace Pjanova, Nadem Soufir, Solrun J Steine, Alexander J Stratigos, Luc Thomas, Julie Tinat, Hensin Tsao, Rūta Veinalde, Margaret A Tucker, Brigitte Bressac-de Paillerets, Julia A Newton-Bishop, Alisa M Goldstein, Lars A Akslen, Anders Molven Journal of Medical Genetics, 2013
Skin examination behavior: The role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination Nadine A. Kasparian, Richard Bränström, Yu-mei Chang, Paul Affleck, Lisa G. Aspinwall, Aad Tibben, Esther Azizi, Orna Baron-Epel, Linda Battistuzzi, William Bruno, May Chan, Francisco Cuellar, Tadeusz Debniak, Dace Pjanova, Slawomir Ertmanski, Adina Figl, Melinda Gonzalez, Nicholas K. Hayward, Marko Hocevar, Peter A. Kanetsky, Sancy Leachman, Wilma Bergman, Olita Heisele, Jane Palmer, Barbara Peric, Susana Puig, Dirk Schadendorf, Nelleke A. Gruis, Julia Newton-Bishop, Yvonne Brandberg, for the Melanoma Genetics Consortium (GenoMEL) Archives of Dermatology, 2012
Inherited variants in the MC1R gene and survival from cutaneous melanoma: A BioGenoMEL study John R. Davies, Juliette Randerson‐Moor, Kairen Kukalizch, Mark Harland, Rajiv Kumar, Srinivasan Madhusudan, Eduardo Nagore, Johan Hansson, Veronica Höiom, Paola Ghiorzo, Nelleke A. Gruis, Peter A. Kanetsky, Judith Wendt, Dace Pjanova, Susana Puig, Philippe Saiag, Dirk Schadendorf, Nadem Soufir, Ichiro Okamoto, Paul Affleck, Zaida García‐Casado, Zighereda Ogbah, Aija Ozola, Paola Queirolo, Antje Sucker, Jennifer H. Barrett, Remco van Doorn, D. Timothy Bishop, Julia Newton‐Bishop Pigment Cell and Melanoma Research, 2012
Prognostic factors and epidemiological characteristics of cutaneous and mucosal head and neck melanoma. Stomatologija Issued by Public Institution Odontologijos Studija Et Al, 2011
Predictors of sun protection behaviors and severe sunburn in an international online study Richard Bränström, Nadine A. Kasparian, Yu-mei Chang, Paul Affleck, Aad Tibben, Lisa G. Aspinwall, Esther Azizi, Orna Baron-Epel, Linda Battistuzzi, Wilma Bergman, William Bruno, May Chan, Francisco Cuellar, Tadeusz Dębniak, Dace Pjanova, Sławomir Ertmański, Adina Figl, Melinda Gonzalez, Nicholas K. Hayward, Marko Hocevar, Peter A. Kanetsky, Sancy A. Leachman, Olita Heisele, Jane Palmer, Barbara Peric, Susana Puig, Dirk Schadendorf, Nelleke A. Gruis, Julia Newton-Bishop, Yvonne Brandberg Cancer Epidemiology Biomarkers and Prevention, 2010
Melanoma risk factors, perceived threat and intentional tanning: An international online survey Richard Bränström, Yu-Mei Chang, Nadine Kasparian, Paul Affleck, Aad Tibben, Lisa G. Aspinwall, Esther Azizi, Orna Baron-Epel, Linda Battistuzzi, William Bruno, May Chan, Francisco Cuellar, Tadeusz Dębniak, Dace Pjanova, Sławomir Ertmański, Adina Figl, Melinda Gonzalez, Nicholas K. Hayward, Marko Hocevar, Peter A. Kanetsky, Samantha L. Leaf, Frans A. van Nieuwpoort, Olita Heisele, Jane Palmer, Barbara Peric, Susana Puig, Althea D. Ruffin, Dirk Schadendorf, Nelleke A. Gruis, Yvonne Brandberg, Julia Newton-Bishop European Journal of Cancer Prevention, 2010
Genetic alteration in melanoma development Dace Pjanova, Kristīne Azarjana, Ingrīda Čēma, Olita Heisele Proceedings of the Latvian Academy of Sciences Section B Natural Exact and Applied Sciences, 2009
Liver progenitor cells perform wound healing in a scratch assay by concerted bistable circuits M Lazovska, K Salmina, D Pjanova, P Zayakin, BI Gerashchenko, ... npj Systems Biology and Applications , 2026 2026
Antigen-specific B cell responses in treatment-naive and chlorambucil-treated patients with chronic lymphocytic leukemia B Šlisere, R Kārkliņš, A Plēgermane, EE Morozova, R Petrovska, ... Scientific Reports , 2026 2026
Resistance of BRAFV600E-mutant melanoma to Vemurafenib: A senescence-induced swing from differentiation to blastulation followed by proliferation F Rumnieks, NM Vainshelbaum, K Salmina, M Lazovska, M Kreismane, ... Cancer Letters, 218430 , 2026 2026 Citations: 1
SARS-CoV-2 Infection and Vaccination, Immune Dysregulation, and Cancer D Pjanova, A Rafeeque Vaccines 14 (3), 255 , 2026 2026
Sambucus nigra cell suspension cultures inhibit SARS-CoV-2 cytopathic effects and display selective antibacterial activity L Balode, E Morozova, A Zīle, E Kaktiņa, MR Baumanis, A Rimša, ... Plant Cell, Tissue and Organ Culture (PCTOC) 164 (3), 70 , 2026 2026
Predictive Role of Clinical and Blood Markers in Melanoma Treated with Immune Checkpoint Inhibitors at the Oncology Centre of Latvia L Mieze, I Vaivode, S Donina, D Pjanova EJC Skin Cancer 4 , 2026 2026
Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028 (vol 10, 104295, 2025) M Donia, H Jespersen, M Jalving, R Lee, H Eriksson, C Hoeller, ... 2026
Corrigendum to “Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028”:[ESMO Open 10 (2025) 104295] M Donia, H Jespersen, M Jalving, R Lee, H Eriksson, C Hoeller, ... ESMO open 11 (1), 105492 , 2026 2026
The value of peritumoral lymphocyte infiltration in progression free survival in TERT and CHEK2 mutant stage I and II melanoma T Zablocka, D Pjanova, S Isajevs JOURNAL OF PATHOLOGY 267 , 2025 2025
The value of peritumoral lymphocyte infiltration in progression-free survival (PFS) of NRAS, TERT and CHEK2 mutant melanoma S Isajevs, T Zablocka, D Pjanova VIRCHOWS ARCHIV 487, S103-S103 , 2025 2025
EFFECT OF LARIFAN ON MONOCYTES OF AGED C57BL/6 AND BALB/C MICE in vitro HG Kononov, AR Dvukhriadkina, KS Ostrovska, RS Dovhyi, MP Rudyk, ... Biotechnologia Acta 18 (3), 34-38 , 2025 2025
Case reports and review of immune checkpoint inhibitor therapy and vitiligo in advanced cutaneous melanoma D Pjanova, S Donina SOUTH EAST EUROPEAN JOURNAL OF IMMUNOLOGY Учредители: Scientific Foundation … , 2025 2025
Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028 M Donia, H Jespersen, M Jalving, R Lee, H Eriksson, C Hoeller, ... ESMO open 10 (3), 104295 , 2025 2025 Citations: 10
IgA class-switched CD27 − CD21 + B cells in IgA nephropathy A Popova, B Slisere, K Racenis, V Kuzema, R Karklins, M Saulite, J Seilis, ... Nephrology Dialysis Transplantation 40 (3), 505-515 , 2025 2025 Citations: 17
Bacteriophage derived dsRNA induces polarized activation of alveolar macrophages from Balb/c and C57Bl/6 mice in vitro in sex-and age-dependent manner R Dovhyi, A Dvukhriadkina, K Ostrovska, M Rudyk, I Verhovcova, ... Cellular Immunology 408, 104916 , 2025 2025 Citations: 1
Effect of Larifan on monocytes of aged C57BL/6 and BALB/C mice in vitro. Biotechnologia Аcta, 18 (3), 34–38 HG Kononov, AR Dvukhriadkina, KS Ostrovska, RS Dovhyi, M Rudyk, ... 2025
Telomere length in hereditary melanoma patients with variants in telomere biology related genes D Pjanova, MK Kreismane EJC Skin Cancer 3 , 2025 2025
Enhanced differentiation of IgA + class-switched CD27 - CD21 + B cells in patients with IgA nephropathy A Popova, B Slisere, K Racenis, V Kuzema, R Karklins, M Saulite, J Seilis, ... Medrxiv, 2024.04. 29.24306572 , 2024 2024 Citations: 1
Liver regeneration by oval cells employing bistability of stemness-senescence, Hippo signaling, EMT-MET, and polyploidy circuit M Lazovska, K Salmina, D Pjanova, BI Gerashchenko, J Erenpreisa BioRxiv, 2024.03. 26.586724 , 2024 2024 Citations: 1
Immunomodulatory properties of bacteriophage derived dsRNA of different size and their use as anticancer vaccine adjuvants N Dobrovolskienė, R Balevičius, A Mlynska, K Žilionytė, JA Krasko, ... Vaccine 42 (3), 512-521 , 2024 2024 Citations: 2
MOST CITED SCHOLAR PUBLICATIONS
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants HE Puntervoll, XR Yang, HH Vetti, IM Bachmann, MF Avril, M Benfodda, ... Journal of medical genetics 50 (4), 264-270 , 2013 2013 Citations: 204
Predictors of sun protection behaviors and severe sunburn in an international online study R Bränström, NA Kasparian, Y Chang, P Affleck, A Tibben, LG Aspinwall, ... Cancer Epidemiology, Biomarkers & Prevention 19 (9), 2199-2210 , 2010 2010 Citations: 155
Toluidine blue test for sperm DNA integrity and elaboration of image cytometry algorithm J Erenpreisa, J Erenpreiss, T Freivalds, M Slaidina, R Krampe, J Butikova, ... Cytometry Part A: The Journal of the International Society for Analytical … , 2003 2003 Citations: 147
Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study JR Davies, J Randerson‐Moor, K Kukalizch, M Harland, R Kumar, ... Pigment cell & melanoma research 25 (3), 384-394 , 2012 2012 Citations: 94
Melanoma risk factors, perceived threat and intentional tanning: an international online survey R Bränström, YM Chang, N Kasparian, P Affleck, A Tibben, LG Aspinwall, ... European Journal of Cancer Prevention 19 (3), 216-226 , 2010 2010 Citations: 80
The cancer aneuploidy paradox: In the light of evolution K Salmina, A Huna, M Kalejs, D Pjanova, H Scherthan, MS Cragg, ... Genes 10 (2), 83 , 2019 2019 Citations: 78
“Mitotic slippage” and extranuclear DNA in cancer chemoresistance: A focus on telomeres K Salmina, A Bojko, I Inashkina, K Staniak, M Dudkowska, P Podlesniy, ... International journal of molecular sciences 21 (8), 2779 , 2020 2020 Citations: 56
CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population D Pjanova, L Engele, JA Randerson-Moor, M Harland, DT Bishop, ... Melanoma research 17 (3), 185-191 , 2007 2007 Citations: 48
Skin examination behavior: the role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination NA Kasparian, R Bränström, Y Chang, P Affleck, LG Aspinwall, A Tibben, ... Archives of dermatology 148 (10), 1142-1151 , 2012 2012 Citations: 44
Inherited variation in the PARP1 gene and survival from melanoma JR Davies, R Jewell, P Affleck, GM Anic, J Randerson‐Moor, A Ozola, ... International journal of cancer 135 (7), 1625-1633 , 2014 2014 Citations: 37
Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. T Delaunay, M Violland, N Boisgerault, S Dutoit, V Vignard, C Münz, ... Oncoimmunology 7 (3), e1407897 , 2018 2018 Citations: 36
An inherited variant in the gene coding for vitamin D‐binding protein and survival from cutaneous melanoma: a B io G eno MEL study JR Davies, S Field, J Randerson‐Moor, M Harland, R Kumar, GM Anic, ... Pigment cell & melanoma research 27 (2), 234-243 , 2014 2014 Citations: 36
Telomere length and survival in primary cutaneous melanoma patients S Rachakonda, N Srinivas, SH Mahmoudpour, Z Garcia-Casado, ... Scientific reports 8 (1), 10947 , 2018 2018 Citations: 34
Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma T Zablocka, M Kreismane, D Pjanova, S Isajevs Oncology Letters 25 (1), 27 , 2022 2022 Citations: 33
Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT NJ Taylor, N Mitra, L Qian, MF Avril, DT Bishop, B Bressac-de Paillerets, ... Journal of the American Academy of Dermatology 81 (2), 386-394 , 2019 2019 Citations: 28
Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study A Zebary, K Omholt, R Van Doorn, P Ghiorzo, K Harbst, CH Johansson, ... Journal of Investigative Dermatology 134 (1), 287-290 , 2014 2014 Citations: 26
Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families NJ Taylor, N Mitra, AM Goldstein, MA Tucker, MF Avril, E Azizi, ... Journal of Investigative Dermatology 137 (12), 2606-2612 , 2017 2017 Citations: 25
Role of the circadian clock “death-loop” in the DNA damage response underpinning cancer treatment resistance NM Vainshelbaum, K Salmina, BI Gerashchenko, M Lazovska, P Zayakin, ... Cells 11 (5), 880 , 2022 2022 Citations: 24
Melanoma epidemiology, prognosis and trends in Latvia K Azarjana, A Ozola, D Ruklisa, I Cema, A Rivosh, A Azaryan, D Pjanova Journal of the European Academy of Dermatology and Venereology 27 (11), 1352 … , 2013 2013 Citations: 23
Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation R Veinalde, A Ozola, K Azarjana, A Molven, LA Akslen, S Donina, ... Melanoma Research 23 (3), 221-226 , 2013 2013 Citations: 22
